

Global Managed Access Program Policy:

Agios is committed to improving the lives of individuals affected by life-altering rare diseases through programs that provide support throughout their journey and help patients and their families explore and access available treatment options.

Our Global Managed Access Program (GMAP) offers a pathway for patients to obtain access to PYRUKYND® (mitapivat) provided they meet the defined criteria and reside in a country where access is permissible under local laws and regulations. Healthcare providers may submit an inquiry on behalf of their patients to Agios for consideration.

Criteria may include, but are not limited to:

- The patient has an illness or condition and doesn't have access to, is no longer responsive to, or is no longer able to tolerate any available treatment option
- The patient isn't eligible/doesn't have access to an Agios clinical trial or clinical trial being conducted by another sponsor
- A benefit-risk analysis, based on the available clinical data as well as the requesting physician's assessment of the patient's condition and medical history, supports making PYRUKYND available
- Sufficient supply of PYRUKYND is readily available

Other criteria and special situations may be considered and reviewed with the treating provider based on the assessment of the patient's condition and medical history

Requesting Access:

Providers may submit an inquiry on behalf of their patient to Agios for consideration. Agios will evaluate all requests in a fair and equitable manner. Requests will be acknowledged within two business days of receipt.

Patients that meet the requirements for access may be candidates to receive therapy; however, Agios cannot guarantee access to its therapies. Access to PYRUKYND will generally continue as long as the patient continues to receive benefit as determined by the treating physician and will end once the therapy becomes commercially available for the relevant indication in the patient's country of residence. However, Agios reserves the right to discontinue, at any time, access to PYRUKYND.